63.99
[]. Arikawa Y, et al. Discovery of a novel pyrrole derivative -[-(2-fluorophenyl)--(pyridin-3-ylsulfonyl)-H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 202, (9), 4446-446.
[2]. Hori Y, et al. -[-(2-Fluorophenyl)--(pyridin-3-ylsulfonyl)-H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 200, 33(), 23-238.
[3]. Sugimoto M, et al. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 209 Jan ;9:60.
H302-H3-H39-H33
P26-P264-P270-P27-P280-P302+P32-P304+P340-P30+P3+P338-P330-P362+P364-P403+P233-P40-P0